Clinical impact of serum prealbumin in pancreaticobiliary disease.
Cholecystitis
Malignant disease
Nutrition
Pancreaticobiliary malignancy
Prealbumin
Journal
Korean journal of clinical oncology
ISSN: 2288-4084
Titre abrégé: Korean J Clin Oncol
Pays: Korea (South)
ID NLM: 9918521386106676
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
06
09
2022
revised:
14
12
2022
accepted:
16
12
2022
entrez:
22
3
2023
pubmed:
23
3
2023
medline:
23
3
2023
Statut:
ppublish
Résumé
Although there are many studies on prealbumin in individual diseases such as malignant or inflammatory diseases, there are few comparative studies. This study aimed to compare the clinical differences between prealbumin levels in cholecystitis and pancreaticobiliary malignancies and investigate the clinical impact of low prealbumin levels in pancreaticobiliary malignancies. From June 2021 to September 2021, 61 patients who had undergone surgery for various pancreaticobiliary diseases were enrolled in this study, and their clinicopathological data were retrospectively analyzed. Many elderly patients with malignant diseases had poor American Society of Anesthesiologists (ASA) scores, significantly lower albumin and prealbumin levels, and higher systemic immune inflammation indices. The low prealbumin group was older; had poorer ASA scores; and had significantly lower body mass index and hemoglobin and albumin levels and higher systemic immune inflammation indices than the normal prealbumin group. In malignant diseases, the low prealbumin group had significantly lower body mass index and hemoglobin levels and a tendency toward more advanced disease (lymph node and distant metastasis). Preoperative low prealbumin levels had an area under the receiver operator characteristic curve of 0.69, suggesting that it may be useful for predicting pancreaticobiliary malignancies. Prealbumin levels were lower in malignant diseases, possibly related to poor nutritional status and systemic immune inflammation. Low prealbumin levels may predict the risk of more advanced disease.
Identifiants
pubmed: 36945244
doi: 10.14216/kjco.22008
pii: kjco-18-2-61
pmc: PMC9942763
doi:
Types de publication
Journal Article
Langues
eng
Pagination
61-65Informations de copyright
Copyright © 2022 Korean Society of Surgical Oncology.
Déclaration de conflit d'intérêts
No potential conflict of interest relevant to this article was reported.
Références
Br J Cancer. 2006 Jun 5;94(11):1568-71
pubmed: 16685271
Nutr Rev. 1995 Apr;53(4 Pt 2):S86-91; discussion S92-4
pubmed: 7644161
Proc Nutr Soc. 1982 Sep;41(3):405-17
pubmed: 6817335
Clin Chem Lab Med. 2002 Dec;40(12):1281-91
pubmed: 12553432
Prog Clin Biol Res. 1990;326:321-34
pubmed: 2405425
J Nutr. 1994 Aug;124(8 Suppl):1433S-1435S
pubmed: 8064398
Biochem Res Int. 2017;2017:9196538
pubmed: 28932602
J Lipid Res. 2000 Jan;41(1):58-65
pubmed: 10627502
Nursing. 2017 Apr;47(4):65-66
pubmed: 28328780
Clin Chem. 2006 Dec;52(12):2177-9
pubmed: 17138848
Ann Surg Oncol. 2010 Dec;17(12):3077-9
pubmed: 20882416
Clin Nutr. 2017 Apr;36(2):364-370
pubmed: 27381508
Eur J Clin Nutr. 2003 Sep;57 Suppl 1:S66-9
pubmed: 12947457
Eur J Clin Nutr. 2002 Aug;56(8):779-85
pubmed: 12122555
Curr Opin Clin Nutr Metab Care. 2009 May;12(3):223-6
pubmed: 19318937
Br J Cancer. 2018 Mar 20;118(6):825-830
pubmed: 29485982
Am J Cardiol. 2008 Jun 2;101(11A):89E-103E
pubmed: 18514634